About This Presentation

1. Guidelines for Prevention and Treatment of Opportunistic Infections in HIV-Infected Adults and AdolescentsParasitic Infections Slide Set Prepared by the AETC National Coordinating Resource Center based on recommendations from the CDC, National Institutes of Health, and HIV Medicine Association/Infectious Diseases Society of America

2. About This Presentation www.aidsetc.org These slides were developed using recommendations published in May 2013. The intended audience is clinicians involved in the care of patients with HIV. Users are cautioned that, because of the rapidly changing field of HIV care, this information could become out of date quickly. Finally, it is intended that these slides be used as prepared, without changes in either content or attribution. Users are asked to honor this intent. -AETC National Resource Center http://www.aidsetc.org

3. Parasites Toxoplasma gondii encephalitis Cryptosporidiosis Microsporidiosis Malaria www.aidsetc.org

4. Toxoplasma gondii encephalitis Epidemiology Clinical Manifestations Diagnosis Prevention Treatment Considerations in Pregnancy www.aidsetc.org

5. Toxoplasma gondii Encephalitis:Epidemiology www.aidsetc.org Caused by the T gondii protozoan Disease almost always caused by reactivation of latent tissue cysts Primary infection may be associated with acute cerebral or disseminated disease Seroprevalence varies widely: 11% in the United States, 50-80% in some European, Latin American, and African countries

6. Toxoplasma gondii Encephalitis: Epidemiology (2) www.aidsetc.org In advanced AIDS, 12-month incidence of TE was 33% among Toxoplasma-seropositive patients who were not on prophylaxis or ART Among seronegative persons, toxoplasmosis is rare Occurs primarily in patients with CD4 counts of <200 cells/µL, especially <50 cells/µL Incidence and mortality lower in United States and Europe owing to widespread use of prophylaxis and potent ART

7. Toxoplasma gondii Encephalitis: Epidemiology (3) www.aidsetc.org Primary infection acquired from tissue cysts in undercooked meat or raw shellfish, or ingestion of sporulated oocysts (from cat feces) in soil, water, or food No transmission by person-to-person contact

8. Toxoplasma gondii Encephalitis: Clinical Manifestations www.aidsetc.org Focal encephalitis with headache, confusion, or motor weakness and fever May have nonfocal symptoms, including nonspecific headache and psychiatric symptoms May have focal neurological abnormalities; may progress to seizures, altered mental status, coma Retinochoroiditis, pneumonia, other organ involvement are rare

9. Toxoplasma gondii Encephalitis: Clinical Manifestations (2) www.aidsetc.org • CT or MRI: • Typical findings are multiple contrast-enhancing lesions in gray matter of cortex or basal ganglia, often associated edema • May show single brain lesion, or diffuse encephalitis without focal lesions

10. Toxoplasma gondii Encephalitis: Diagnosis www.aidsetc.org • Serum anti-Toxoplasma IgG • Positive in almost all patients with TE; negative IgG makes diagnosis unlikely but not impossible • IgM usually negative • Definitive diagnosis: compatible clinical syndrome + mass lesion(s) on imaging + detection of organism in a clinical sample (brain biopsy) • CT, MRI of brain: typically multiple contrast-enhancing lesions, often with edema • MRI better than CT for radiological diagnosis • PET or SPECT may help distinguish TE from lymphoma

11. Toxoplasma gondii Encephalitis: Diagnosis (2) www.aidsetc.org Check CSF (if safe and feasible) for T gondii PCR, cytology, culture, cryptococcal antigen, PCR for M tuberculosis, EBV, JC virus CSF PCR specificity for T gondii is 96-100%, sensitivity 50%

12. Toxoplasma gondii Encephalitis: Diagnosis (3) www.aidsetc.org • Differential diagnosis of focal neurological disease • CNS lymphoma, PML, mycobacterial infection (TB), fungal infection, Chagas disease, abscess

13. Toxoplasma gondii Encephalitis: Diagnosis (4) • CT scan of the brain showing contrast-enhancing lesion of toxoplasmosis Credit: P. Volberding, MD; UCSF Center for HIV Information Image Library www.aidsetc.org

14. Toxoplasma gondii Encephalitis: Diagnosis (5) www.aidsetc.org May initially make empiric diagnosis, established on basis of clinical and radiographic improvement to TE therapy, in absence of a likely alternative diagnosis Brain biopsy if failure to respond to therapy, or if initial studies suggest etiology other than TE

15. Toxoplasma gondii Encephalitis: Preventing Exposure www.aidsetc.org • All HIV+ should be tested for IgG to Toxoplasma at baseline, to detect latent infection • Toxoplasma seronegative: counsel about sources of infection • Patients: avoid eating raw or undercooked meat or shellfish; wash hands after handling raw meat and after contact with soil; wash fruits/vegetables; clean cat-litter boxes daily and wash hands afterward; cats should notbe fed raw/undercooked meats

16. Toxoplasma gondii Encephalitis: Primary Prophylaxis www.aidsetc.org • For all Toxoplasma IgG positive with CD4 count <100 cells/µL • Recommended: • TMP-SMX 1 DS QD • Alternative: • TMP-SMX 1 DS PO TIW • TMP-SMX 1 SS QD • Dapsone* 50 mg PO QD + pyrimethamine 50 mg PO Q week + leucovorin 25 mg PO Q week • Dapsone* 200 mg PO Q week + pyrimethamine 75 mg PO Q week + leucovorin 25 mg PO Q week • Atovaquone 1,500 mg PO QD +/- pyrimethamine 25 mg PO QD + leucovorin 10 mg PO QD * Avoid dapsone if patient has G6PD deficiency; screen before treatment with dapsone, if possible.

17. Toxoplasma gondii Encephalitis: Primary Prophylaxis (2) www.aidsetc.org Toxoplasma seronegative patients: retest for Toxoplasma IgG if CD4 count declines to <100 cells/µL, unless taking PCP prophylaxis that also is active against TE

18. Toxoplasma gondii Encephalitis: Discontinuing Primary Prophylaxis www.aidsetc.org Discontinue if on effective ART with CD4 count of >200 cells/µL for >3 months Restart prophylaxis if CD4 count decreases to <100-200 cells/µL

19. Toxoplasma gondii Encephalitis: Treatment www.aidsetc.org • Preferred: • Pyrimethamine 200 mg PO 1 dose, then: • For weight ≤60 kg: pyrimethamine 50 mg PO QD + sulfadiazine 1,000 mg PO Q6H + leucovorin 10-25 mg PO QD • For weight >60 kg: pyrimethamine 75 mg PO QD + sulfadiazine 1,500 mg PO Q6H + leucovorin 10-25 mg PO QD • Duration: ≥6 weeks, longer if extensive disease or incomplete response at 6 weeks

20. Toxoplasma gondii Encephalitis: Treatment (2) www.aidsetc.org • Alternative: • Pyrimethamine as above + clindamycin 600 mg IV or PO Q6H + leucovorin as above • TMP-SMX (5 mg/kg TMP and 25 mg/kg SMX) IV or PO BID • Atovaquone 1,500 mg PO BID + pyrimethamine, as above + leucovorin as above • Atovaquone 1,500 mg PO BID + sulfadiazine (weight-based as above) • Atovaquone 1,500 mg PO BID (variable absorption) • Pyrimethamine as above + azithromycin 900-1,200 mg PO QD + leucovorin as above

21. Toxoplasma gondii Encephalitis: Treatment (3) www.aidsetc.org • Adjunctive corticosteroids only if indicated for treatment of mass effect; monitor closely and discontinue as soon as possible • Anticonvulsants if history of seizures; continue at least through period of acute therapy • Should not be given prophylactically to all patients

22. Toxoplasma gondii Encephalitis: ART Initiation www.aidsetc.org • No data to guide recommendation on when to start ART • Many recommend starting ART within 2-3 weeks after diagnosis of TE • In one study, lower rate of AIDS progression or death with early ART

23. Toxoplasma gondii Encephalitis: Monitoring and Adverse Events www.aidsetc.org • Follow clinical and radiologic improvement • Ab titers not useful • Monitor for adverse events • Pyrimethamine: rash, nausea, bone marrow suppression • May be reversed with increase in leucovorin dosage • Sulfadiazine: rash, fever, leukopenia, hepatitis, nausea, vomiting, diarrhea, renal insufficiency, crystalluria • Clindamycin: rash, fever, nausea, diarrhea (including Clostridium difficile colitis), hepatotoxicity • TMP-SMX: rash, fever, leukopenia, thrombocytopenia, hepatotoxicity • Atovaquone: nausea, vomiting, diarrhea, rash, headache, hyperglycemia, fever

24. Toxoplasma gondii Encephalitis: Monitoring and Adverse Events (2) www.aidsetc.org IRIS appears to occur rarely

25. Toxoplasma gondii Encephalitis: Treatment Failure www.aidsetc.org • Clinical or radiologic deterioration during first week of therapy, or lack of clinical improvement within 10-14 days • Brain biopsy, if not done previously • If confirmed TE, consider switch to alternative treatment regimen • In patients who adhere to treatment, recurrence is unusual during maintenance therapy following initial clinical and radiographic response

26. Toxoplasma gondii Encephalitis: Preventing Recurrence www.aidsetc.org • Secondary prophylaxis: • Preferred: • Pyrimethamine 25-50 mg PO QD + sulfadiazine 2,000-4,000 mg PO daily in 2-4 divided doses + leucovorin 10-25 mg PO QD • Alternative: • Clindamycin 600 mg PO Q8H + pyrimethamine 25-50 mg PO QD + leucovorin 10-25 mg PO QD (not effective as PCP prophylaxis) • TMP-SMX DS 1 tablet BID • Atovaquone 750-1,500 mg PO BID + pyrimethamine 25 mg PO QD (+ leucovorin 10 mg PO QD) • Atovaquone 750-1,500 mg PO BID + sulfadiazine 2,000-4,000 mg PO daily in 2-4 divided doses • Atovaquone 750-1,500 mg PO BID

27. Toxoplasma gondii Encephalitis: Preventing Recurrence (2) www.aidsetc.org • Discontinuing maintenance therapy: consider in asymptomatic patients after successful initial therapy for TE, resolution of signs and symptoms of TE, and sustained increase in CD4 count to >200 cells/µL for >6 months, on ART • Consider brain MRI before treatment discontinuation; continue therapy if mass lesions present or enhancement persists • Restart secondary prophylaxis if CD4 count decreases to <200 cells/µL

28. Toxoplasma gondii Encephalitis: Considerations in Pregnancy www.aidsetc.org Check T gondii IgG during pregnancy If suspected or confirmed T gondii infection, evaluate and manage with a maternal-fetal specialist Diagnostic considerations same as for nonpregnant women

29. Toxoplasma gondii Encephalitis: Considerations in Pregnancy (2) www.aidsetc.org • Perinatal transmission usually occurs only with acute maternal infection; case reports of transmission with reactivation of chronic infection in women with severe immunosuppression • If toxoplasmosis during pregnancy (primary infection or reactivation of chronic toxoplasmosis): • Detailed ultrasound of fetus • Consider PCR of amniotic fluid in select circumstances • Neonate should be evaluated for evidence of congenital infection

30. Toxoplasma gondii Encephalitis: Considerations in Pregnancy (3) www.aidsetc.org • Primary prophylaxis: recommended • TMP-SMX preferred • Balance possible risks with expected benefits • Treatment: as in nonpregnant adults • Secondary prophylaxis: as in nonpregnant women

31. Toxoplasma gondii Encephalitis: Considerations in Pregnancy (4) www.aidsetc.org Pyrimethamine appears safe in human pregnancy Sulfadiazine appears safe though, if given around time of delivery, may increase risk of neonatal kernicterus Clindamycin considered same in pregnancy Dapsone: risk of mild maternal hemolysis with long-term therapy; low risk of hemolytic anemia in exposed fetuses with G6PD deficiency

32. Toxoplasma gondii Encephalitis: Considerations in Pregnancy (5) www.aidsetc.org Consider immediate initiation of ART, to decrease risk of perinatal HIV transmission, especially for women diagnosed with TE in 3rd trimester Preconception care for women receiving TE prophylaxis: discuss option of deferring pregnancy until TE prophylaxis can be discontinued safely

33. Cryptosporidiosis Epidemiology Clinical Manifestations Diagnosis Prevention Treatment Considerations in Pregnancy www.aidsetc.org

34. Cryptosporidiosis: Epidemiology www.aidsetc.org • Caused by Cryptosporidium species • Protozoan parasites • Infect small intestine mucosa; in immunosuppressed patients, also infect large intestine and other sites • Advanced immunosuppression (eg, CD4 <100 cells/µL) associated with prolonged, severe, or extraintestinal disease

35. Cryptosporidiosis: Epidemiology (2) www.aidsetc.org • Infection results from ingestion of oocysts excreted in feces of infected humans or animals • Water supplies and recreational water sources (oocysts may withstand standard chlorination) • Person-to-person transmission common, via oral-anal contact, from infected children to adults (eg, during diapering), or care of patients with diarrhea

36. Cryptosporidiosis: Epidemiology (3) www.aidsetc.org Common cause of chronic diarrhea in AIDS patients in developing countries In developed countries with low rates of envrionmental contamination and widespread use of effective ART, <1 case per 1,000 person-years in AIDS patients

37. Cryptosporidiosis: Clinical Manifestations www.aidsetc.org Acute or subacute onset of profuse watery, nonbloody diarrhea, often with nausea, vomiting, and abdominal cramping Fever in 1/3 of patients Can be very severe, especially with immune suppression Malabsorption is common; dehydration, electrolyte abnormalities, malnutrition may result Biliary tract and pancreatic duct may be infected, causing scleroding cholangitis and pancreatitis Pulmonary infection is possible

38. Cryptosporidiosis: Diagnosis www.aidsetc.org • Microscopic identification of oocysts in stool or tissue • DFA very sensitive, specific, is current gold standard for stool specimens • Acid-fast staining often used • PCR extremely sensitive • ELISA or immunochromatographic tests • Small intestine biopsy with identification of Cryptosporidium organisms

39. Cryptosporidiosis: Diagnosis (2) www.aidsetc.org • Single specimen usually sufficient in profuse diarrhea • Repeat stool sampling is recommended in mild disease

40. Cryptosporidiosis: Prevention www.aidsetc.org • Preventing exposure • Avoid exposure to infected contacts • Contact with diarrhea • Potential oral exposure to feces during sex • Direct contact with farm animals, stool from pets • Scrupulous handwashing after potential contact with feces (eg, after diapering), after handling pets or other animals, gardening, before preparing food or eating, before and after sex

41. Cryptosporidiosis: Prevention (2) www.aidsetc.org • Avoid exposure to contaminated water, food • Do not drink or swallow water from recreational sources (lakes, streams, pools) • Ice, fountain beverages, water fountains may be contaminated • Avoid raw oysters

42. Cryptosporidiosis: Prevention (3) www.aidsetc.org • Boil tap water for ≥1 minute during outbreaks or when community advisory is issued • Submicron water filters or bottled water may reduce risk • For non-outbreak settings, data are inadequate to recommend that all persons with low CD4 counts avoid drinking tap water • Consider drinking only filtered water

43. Cryptosporidiosis: Prevention (4) www.aidsetc.org • Preventing disease • Primary prophylaxis: • Appropriate initiation of ART before severe immunosuppression should prevent disease • Rifabutin and possibly clarithromycin are protective, but data insufficient to recommend as chemoprophylaxis

44. Cryptosporidiosis: Treatment www.aidsetc.org • Preferred strategies • ART with immune restoration (to CD4 count >100 cells/µL) • Usually results in complete resolution; should be offered as part of initial management of cryptosporidiosis • Symptomatic treatment: antidiarrheals • Tincture of opium may be more effective than loperamide • Octreotide usually not recommended (no more effective than other antidiarrheals) • Supportive care: aggressive hydration, electrolyte repletion, nutritional support (IV therapies may be needed)

45. Cryptosporidiosis: Treatment (2) www.aidsetc.org • Alternative strategies • No consistently effective antimicrobial therapy in absence of ART • Consider nitazoxanide or other antiparasitic drugs in conjunction with ART, not instead of ART • Nitazoxanide 500-1,000 mg PO BID for 14 days + ART and other measures above • Some studies show clinical improvement with nitazoxanide • Paromomycin 500 mg PO QID for 14-21 days + ART and other measures above • Limited data; may improve clinical response in conjunction with ART

46. Cryptosporidiosis: Starting ART www.aidsetc.org ART should be offered as part of initial management of this infection PIs inhibit Cryptosporidium in animal models – some experts prefer PI-based ART

47. Cryptosporidiosis: Monitoring and Adverse Events www.aidsetc.org • Monitor closely for volume depletion, electrolyte loss, weight loss, and malnutrition • TPN may be indicated • IRIS not reported

48. Cryptosporidiosis: Treatment Failure www.aidsetc.org Supportive treatment Optimization of ART

49. Cryptosporidiosis: Prevention of Recurrence www.aidsetc.org No effective prevention, other than immune restoration with ART

50. Cryptosporidiosis: Considerations in Pregnancy www.aidsetc.org • Rehydration and ART initiation as with nonpregnant adults • Nitazoxanide not teratogenic in animals, but no data in pregnant humans • Use after 1st trimester in severely symptomatic women • Paromomycin: limited information on teratogenicity; minimal systemic absorption with PO administration • Use after 1st trimester in severely symptomaticwomen